http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jul 2024 08:06:23 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Board+Changes/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html <p>NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the general meeting of shareholders at the next annual general meeting. Additionally, NewAmsterdam announced the http://www.streetinsider.com/Board+Changes/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html Thu, 18 Jul 2024 08:06:23 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Board+Changes/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html <p>NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the general meeting of shareholders at the next annual general meeting. Additionally, NewAmsterdam announced the http://www.streetinsider.com/Board+Changes/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html Thu, 18 Jul 2024 08:06:23 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Board+Changes/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html <p>NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the general meeting of shareholders at the next annual general meeting. Additionally, NewAmsterdam announced the http://www.streetinsider.com/Board+Changes/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html Thu, 18 Jul 2024 08:06:23 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Board+Changes/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html <p>NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the general meeting of shareholders at the next annual general meeting. Additionally, NewAmsterdam announced the http://www.streetinsider.com/Board+Changes/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html Thu, 18 Jul 2024 08:06:23 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Board+Changes/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html <p>NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the general meeting of shareholders at the next annual general meeting. Additionally, NewAmsterdam announced the http://www.streetinsider.com/Board+Changes/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html Thu, 18 Jul 2024 08:06:23 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Corporate+News/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html <p>NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the general meeting of shareholders at the next annual general meeting. Additionally, NewAmsterdam announced the http://www.streetinsider.com/Corporate+News/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html Thu, 18 Jul 2024 08:06:23 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Corporate+News/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html <p>NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the general meeting of shareholders at the next annual general meeting. Additionally, NewAmsterdam announced the http://www.streetinsider.com/Corporate+News/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html Thu, 18 Jul 2024 08:06:23 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Corporate+News/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html <p>NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the general meeting of shareholders at the next annual general meeting. Additionally, NewAmsterdam announced the http://www.streetinsider.com/Corporate+News/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html Thu, 18 Jul 2024 08:06:23 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Corporate+News/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html <p>NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the general meeting of shareholders at the next annual general meeting. Additionally, NewAmsterdam announced the http://www.streetinsider.com/Corporate+News/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html Thu, 18 Jul 2024 08:06:23 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Corporate+News/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html <p>NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the general meeting of shareholders at the next annual general meeting. Additionally, NewAmsterdam announced the http://www.streetinsider.com/Corporate+News/NewAmsterdam+Pharma+%28NAMS%29+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477588.html Thu, 18 Jul 2024 08:06:23 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Press+Releases/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html <p align="justify">NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the http://www.streetinsider.com/Press+Releases/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html Thu, 18 Jul 2024 08:00:00 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Press+Releases/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html <p align="justify">NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the http://www.streetinsider.com/Press+Releases/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html Thu, 18 Jul 2024 08:00:00 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Press+Releases/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html <p align="justify">NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the http://www.streetinsider.com/Press+Releases/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html Thu, 18 Jul 2024 08:00:00 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Press+Releases/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html <p align="justify">NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the http://www.streetinsider.com/Press+Releases/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html Thu, 18 Jul 2024 08:00:00 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Press+Releases/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html <p align="justify">NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the http://www.streetinsider.com/Press+Releases/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html Thu, 18 Jul 2024 08:00:00 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Globe+Newswire/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html <p align="justify">NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the http://www.streetinsider.com/Globe+Newswire/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html Thu, 18 Jul 2024 08:00:00 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Globe+Newswire/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html <p align="justify">NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the http://www.streetinsider.com/Globe+Newswire/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html Thu, 18 Jul 2024 08:00:00 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Globe+Newswire/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html <p align="justify">NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the http://www.streetinsider.com/Globe+Newswire/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html Thu, 18 Jul 2024 08:00:00 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Globe+Newswire/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html <p align="justify">NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the http://www.streetinsider.com/Globe+Newswire/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html Thu, 18 Jul 2024 08:00:00 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Globe+Newswire/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html <p align="justify">NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the http://www.streetinsider.com/Globe+Newswire/NewAmsterdam+Pharma+Announces+Appointments+of+Mark+C.+McKenna+and+Wouter+Joustra+to+its+Board+of+Directors/23477393.html Thu, 18 Jul 2024 08:00:00 -0400 APGE ENGN NAMS SYRE VECT http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html Mon, 08 Jul 2024 07:00:00 -0400 ALDR IMTX IRWD VECT http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html Mon, 08 Jul 2024 07:00:00 -0400 ALDR IMTX IRWD VECT http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html Mon, 08 Jul 2024 07:00:00 -0400 ALDR IMTX IRWD VECT http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson http://www.streetinsider.com/Press+Releases/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html Mon, 08 Jul 2024 07:00:00 -0400 ALDR IMTX IRWD VECT http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html <p><strong>PRESS RELEASE </strong></p> <p align="center"><strong>Memo Therapeutics AG appoints Paul Carter as Chairperson</strong></p> <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV </em></li><li style="list-style-position:inside; text-align:center;"><em>Extensive public and private market experience following executive positions in numerous biopharma companies</em></li></ul> <p>                </p> <p align="justify"><strong>Schlieren / Zurich, Switzerland, 8</strong> <strong>July, 2024 – </strong><a href="https://www.globenewswire.com/Tracker?data=gmJyEQ15mPpAd-ZFpUWNqeSx_H-0uSSIGOaDGPHJF1a69pnmAPZvHaVKW8T-LDuCFrrCQpctsUtGJEJRKyvARoomGFRIqbika1RZ3AWeIH3bMiK8EtVeWeUyMKkg0bVD" rel="nofollow" target="_blank">Memo Therapeutics AG</a> (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson http://www.streetinsider.com/Globe+Newswire/Memo+Therapeutics+AG+appoints+Paul+Carter+as+Chairperson/23438693.html Mon, 08 Jul 2024 07:00:00 -0400 ALDR IMTX IRWD VECT